Disease on EC 1.1.1.51 - 3(or 17)beta-hydroxysteroid dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
"Any decision is better than none" decision-making about sex of rearing for siblings with 17beta-hydroxysteroid-dehydrogenase-3 deficiency.
17 alpha-hydroxylation deficiency.
17 beta-hydroxysteroid dehydrogenase deficiency in malignant interstitial cell carcinoma of the testis.
17 beta-hydroxysteroid dehydrogenase deficiency with minimal virilization and spontaneous reduction of serum androgens to normal female levels.
17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite.
17beta-hydroxysteroid dehydrogenase type 3 deficiency as a result of a homozygous 7 base pair deletion in 17betaHSD3 gene.
17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal.
17beta-Hydroxysteroid dehydrogenase-3 deficiency: from pregnancy to adolescence.
3 alpha-Androstanediol glucuronide in premature and normal pubarche.
3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism.
3 beta-hydroxysteroid dehydrogenase deficiency. Follow-up study in a girl with pubertal bone age.
3beta-hydroxysteroid dehydrogenase/delta5-->4-isomerase activity associated with the human 17beta-hydroxysteroid dehydrogenase type 2 isoform.
46,XY DSD with Female or Ambiguous External Genitalia at Birth due to Androgen Insensitivity Syndrome, 5alpha-Reductase-2 Deficiency, or 17beta-Hydroxysteroid Dehydrogenase Deficiency: A Review of Quality of Life Outcomes.
A case of late-onset congenital adrenal hyperplasia due to partial 3 beta-hydroxysteroid dehydrogenase deficiency.
A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty.
A novel missense mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene in a family with classical salt-wasting congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
A study of gender outcome of Egyptian patients with 46,XY disorder of sex development.
Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche.
Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics.
Anti-müllerian hormone in children with androgen insensitivity.
Characterization of two novel homozygous missense mutations involving codon 6 and 259 of type II 3beta-hydroxysteroid dehydrogenase (3betaHSD) gene causing, respectively, nonsalt-wasting and salt-wasting 3betaHSD deficiency disorder.
Clinical, endocrine, and molecular findings in 17beta-hydroxysteroid dehydrogenase type 3 deficiency.
Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency.
Complexities of gender assignment in 17beta-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for early orchiectomy?
Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Congenital adrenal hyperplasia in pregnancy.
Congenital adrenal hyperplasia in Turkey: a review of 273 patients.
Congenital adrenal hyperplasia owing to 3 beta-hydroxysteroid dehydrogenase deficiency.
Congenital adrenal hyperplasia.
Defects in steroidogenic enzymes. Discrepancies between clinical steroid research and molecular biology results.
Detection of 3 beta-hydroxysteroid dehydrogenase deficiency in a newborn by means of urinary steroid analysis.
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
Dihydrotestosterone binding by cultured human fibroblasts. Comparison of cells from control subjects and from patients with hereditary male pseudohermaphroditism due to androgen resistance.
Familial male pseudohermaphroditism with gynaecomastia due to 17 beta-hydroxysteroid dehydrogenase deficiency. A report of 3 cases.
Genetic defects of steroidogenesis in premature pubarche.
Genetic diseases of steroid metabolism.
High prevalence of abnormal adrenal response in girls with central precocious puberty at early pubertal stages.
Hirsutism due to late onset 3 beta-hydroxysteroid dehydrogenase deficiency.
Hyperandrogenism due to 3 beta-hydroxysteroid dehydrogenase deficiency with accessory adrenocortical tissue: a hormonal and metabolic evaluation.
Hyperandrogenism in female adolescents.
Hypothalamic-pituitary-gonadal axis function in pubertal male and female siblings with glucocorticoid-treated nonsalt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
Isolated precocious pubarche: an approach.
Late-onset 3 beta-hydroxysteroid dehydrogenase deficiency with virilization induced by a large ovarian cyst.
Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women.
Male pseudohermaphroditism consistent with 17,20-desmolase deficiency.
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: gender reassignment in early infancy.
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: studies on the natural history of the defect and effect of androgens on gender role.
Male pseudohermaphroditism due to 3 beta-hydroxysteroid dehydrogenase-isomerase deficiency associated with atrial septal defect.
Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: gender role change and absence of gynecomastia at puberty.
Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty.
Masculinizing genitoplasty in intersex patients.
Mechanisms of androgen production in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency in children with accelerated growth, premature pubarche and/or hirsutism.
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency with hyperaldosteronism.
Molecular analysis of type II 3 beta-hydroxysteroid dehydrogenase gene in Japanese patients with classical 3 beta-hydroxysteroid dehydrogenase deficiency.
Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency.
Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency.
Mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene in a patient with classic salt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
Neutral 17beta-hydroxysteroid oxidoreductase deficiency in testes causing male pseudohermaphroditism in an infant.
New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes.
Non-classical 3 beta-hydroxysteroid dehydrogenase deficiency in children in central Iowa. Difficulties in differentiating this entity from cases of precocious adrenarche without an adrenal enzyme defect.
Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency in young girls with hirsutism and premature pubarche.
Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency: a review of our experience with 25 female patients.
Nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function.
Normal ovarian function in a mild form of late-onset 3 beta-hydroxysteroid dehydrogenase deficiency.
Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male.
Pediatric disorders of sex development.
Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Plasma and urinary androgens and oestrogens in a pubertal boy with 3 beta-hydroxysteroid dehydrogenase deficiency.
Possible testicular 3 beta-hydroxysteroid dehydrogenase deficiency in cryptorchid neonates.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Proceedings: 17beta-hydroxysteroid oxidoreductase deficiency causing male pseudohermaphroditism in a child.
Progressive virilization of a pubertal phenotypic female: 17 beta-hydroxysteroid dehydrogenase deficiency.
Pubertal changes in testicular 3 beta-hydroxysteroid dehydrogenase activity in a male with classical 3 beta-hydroxysteroid dehydrogenase deficiency showing spontaneous secondary sexual maturation.
Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping.
Regulation of Wolffian duct development.
Sigmoid reconfigured vaginal construction in children.
Steroid metabolism in testes of patients with incomplete masculinization due to androgen insensitivity or 17 beta-hydroxysteroid dehydrogenase deficiency and normally differentiated males.
Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency.
Ten years experience with masculinizing genitoplasty in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens.
The Dilemma of Sex Reassignment in an Adolescent with 17beta-HSD-3 Deficiency Raised as a Female: Ten-Year Follow-Up.
The incidence of late-onset congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency among hirsute women.
The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia.
The response to human chorionic gonadotropin (HCG) administration in boys with and without delta5-3beta-hydroxysteroid dehydrogenase deficiency.
Treatment of clitoromegaly of culturally diverse patients.
Urinary 5-ene-steroid excretion in non-classical congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency (NC-3BHSD).
Use of laparoscopy in intersex patients.
[17 beta-Hydroxysteroid dehydrogenase deficiency]
[17beta-hydroxysteroid dehydrogenase deficiency]
[3 beta-hydroxysteroid dehydrogenase deficiency and 21-hydroxylase deficiency in hirsutism]
[3 beta-Hydroxysteroid dehydrogenase deficiency]
[Case report: congenital adrenal hyperplasia and ambiguous genitalia due to 3 beta-hydroxysteroid dehydrogenase deficiency]
[Dehydroepiandrosterone and dehydroepiandrosterone-sulfate content of the amniotic fluid]
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
[Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency]
[Partial 3-beta-hydroxysteroid dehydrogenase deficiencies]
[Severe 46,XY virilization deficit due to 17beta-hydroxysteroid dehydrogenase deficiency]
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
Masculinizing genitoplasty in intersex patients.
3alpha(17beta)-hydroxysteroid dehydrogenase (nad+) deficiency
Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency.
3beta-hydroxy-delta5-steroid dehydrogenase deficiency
The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.
3beta-hydroxysteroid 3-dehydrogenase deficiency
Masculinizing genitoplasty in intersex patients.
46, XY Disorders of Sex Development
17 alpha-hydroxylation deficiency.
Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics.
Dihydrotestosterone binding by cultured human fibroblasts. Comparison of cells from control subjects and from patients with hereditary male pseudohermaphroditism due to androgen resistance.
Familial male pseudohermaphroditism with gynaecomastia due to 17 beta-hydroxysteroid dehydrogenase deficiency. A report of 3 cases.
Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3.
Male pseudohermaphroditism caused by nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency.
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management.
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: gender reassignment in early infancy.
Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: studies on the natural history of the defect and effect of androgens on gender role.
Male pseudohermaphroditism due to 3 beta-hydroxysteroid dehydrogenase-isomerase deficiency associated with atrial septal defect.
Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: gender role change and absence of gynecomastia at puberty.
Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty.
Masculinizing genitoplasty in intersex patients.
Mechanisms of androgen production in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
Mutation in the human gene for 3 beta-hydroxysteroid dehydrogenase type II leading to male pseudohermaphroditism without salt loss.
Neutral 17beta-hydroxysteroid oxidoreductase deficiency in testes causing male pseudohermaphroditism in an infant.
Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene.
Proceedings: 17beta-hydroxysteroid oxidoreductase deficiency causing male pseudohermaphroditism in a child.
Ten years experience with masculinizing genitoplasty in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.
[Elevated levels of plasma 4-ene steroids in a case of congenital deficiency of 3 beta-hydroxysteroid dehydrogenase]
[Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency]
Acne Vulgaris
Androgen metabolism in sebaceous glands from subjects with and without acne.
Cutaneous androgen metabolism: basic research and clinical perspectives.
Testosterone synthesized in cultured human SZ95 sebocytes derives mainly from dehydroepiandrosterone.
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
Addison Disease
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Adenocarcinoma
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in normal and carcinomatous endometrium.
Effect of gestagen therapy upon 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma.
Immunohistochemical study of the human 17 beta-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma.
Short-term effects of danazol and medroxyprogesterone acetate on cytosol and nuclear estrogen and progestin receptors, 17 beta-hydroxysteroid dehydrogenase activity, histopathology, and ultrastructure of human endometrial adenocarcinoma.
Steroid sulphotransferase and 17beta-hydroxysteroid dehydrogenase activities in Ishikawa human endometrial adenocarcinoma cells.
[Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)]
Adenoma
Acid phosphatases of dog testis and a Leydig cell tumor.
High expression of cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome associated with high secretion of adrenal androgens.
Increased 17 beta-hydroxysteroid dehydrogenase activity in a masculinizing adrenal adenoma in a patient with isolated testosterone overproduction.
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Primary aldosteronism associated with chronic renal failure. Report of a case.
Primary aldosteronism: treatment with trilostane.
Steroid biosynthesis in human adrenal tumors.
Adenomyosis
Endometriosis: the pathophysiology as an estrogen-dependent disease.
[Temporal and spatial expression of estrogen activity-related molecules in eutopic endometrium of adenomyosis]
Adrenal Hyperplasia, Congenital
A case of late-onset congenital adrenal hyperplasia due to partial 3 beta-hydroxysteroid dehydrogenase deficiency.
A new compound heterozygous frameshift mutation in the type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene causes salt-wasting 3 beta-HSD deficiency congenital adrenal hyperplasia.
A novel missense mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene in a family with classical salt-wasting congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Absence of molecular defect in the type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene in premature pubarche children and hirsute female patients with moderately decreased adrenal 3 beta-HSD activity.
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin.
Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase type II deficiency in 4 Saudi children. Long term follow up.
Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene.
Congenital adrenal hyperplasia in Turkey: a review of 273 patients.
Congenital adrenal hyperplasia owing to 3 beta-hydroxysteroid dehydrogenase deficiency.
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia.
Hypothalamic-pituitary-gonadal axis function in pubertal male and female siblings with glucocorticoid-treated nonsalt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
Hypothalamic-pituitary-gonadal function in two infants with Smith-Lemli-Opitz syndrome.
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
Late onset adrenal hyperplasia due to 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency in north Indian hirsute women.
Male pseudohermaphroditism caused by nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency.
Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency.
Molecular genetics of congenital adrenal hyperplasia.
Mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene in a patient with classic salt-wasting 3 beta-hydroxysteroid dehydrogenase deficiency congenital adrenal hyperplasia.
Nonsalt-losing congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency with normal glomerulosa function.
Persistent testicular delta5-isomerase-3beta-hydroxysteroid dehydrogenase (delta5-3beta-HSD) deficiency in the delta5-3beta-HSD form of congenital adrenal hyperplasia.
Prevention of Mammary gland defects in experimental congenital adrenal hyperplasia due to inhibition to 3 beta-hydroxysteroid dehydrogenase in rats.
Sigmoid reconfigured vaginal construction in children.
Studies of 3 beta-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated delta 5-steroid levels.
The incidence of late-onset congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency among hirsute women.
Urinary 5-ene-steroid excretion in non-classical congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency (NC-3BHSD).
[Case report: congenital adrenal hyperplasia and ambiguous genitalia due to 3 beta-hydroxysteroid dehydrogenase deficiency]
[Dehydroepiandrosterone and dehydroepiandrosterone-sulfate content of the amniotic fluid]
Adrenocortical Adenoma
Enzyme histo-cytochemical studies in human adrenocortical adenomas. [II] Cushing's syndrome.
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Small adrenocortical tumors without apparent clinical endocrine abnormalities. Immunolocalization of steroidogenic enzymes.
Adrenocortical Carcinoma
Decrease in the expression of the 3beta-hydroxysteroid dehydrogenase gene in human adrenal tissue during prepuberty and early puberty: implications for the mechanism of adrenarche.
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Adrenogenital Syndrome
The adrenogenital syndrome with deficiency of 3 beta-hydroxysteroid dehydrogenase.
[Unusual adrenogenital syndrome. Probable blockade of 3 beta-hydroxysteroid dehydrogenase in a 4-year-old boy]
Alzheimer Disease
Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model.
Aging and Lateralization of the Rat Brain on a Biochemical Level.
Androgen-Insensitivity Syndrome
17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal.
46,XY DSD with Female or Ambiguous External Genitalia at Birth due to Androgen Insensitivity Syndrome, 5alpha-Reductase-2 Deficiency, or 17beta-Hydroxysteroid Dehydrogenase Deficiency: A Review of Quality of Life Outcomes.
Anti-müllerian hormone in children with androgen insensitivity.
Masculinizing genitoplasty in intersex patients.
Practical approach to steroid 5alpha-reductase type 2 deficiency.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Regulation of Wolffian duct development.
Use of laparoscopy in intersex patients.
aromatase deficiency
Ovarian steroidogenesis in Japanese patients with polycystic ovary syndrome.
Autoimmune Diseases
Human leukocyte antigen-DQB1* genotypes encoding aspartate at position 57 are associated with 3beta-hydroxysteroid dehydrogenase autoimmunity in premature ovarian failure.
Identification of 3 beta-hydroxysteroid dehydrogenase as a novel target of steroid cell autoantibodies: association of autoantibodies with endocrine autoimmune disease.
Bladder Exstrophy
Sigmoid reconfigured vaginal construction in children.
Breast Neoplasms
1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase.
17 beta-estradiol dehydrogenase (E2DH) activity in T47D cells.
17 Beta-hydroxysteroid dehydrogenase and aromatase activity in breast fat from women with benign and malignant breast tumours.
17 beta-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin.
17 Beta-hydroxysteroid dehydrogenase in human breast cancer: analysis of kinetic and clinical parameters.
17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
A comparison of the in vivo uptake and metabolism of 3H-oestrone and 3H-oestradiol by normal breast and breast tumour tissues in post-menopausal women.
A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro.
Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8.
Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism.
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women.
Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue.
Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues.
Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells.
Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.
Effect of nomegestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells.
Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells.
Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells.
Estradiol 17 beta-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency.
Estradiol as an anti-aromatase agent in human breast cancer cells.
Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures.
Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence.
Genetic susceptibility to cancer from exogenous and endogenous exposures.
Genomic data on breast cancer transcript profile modulation by 17beta-hydroxysteroid dehydrogenase type 1 and 17-beta-estradiol.
Hormonal carcinogenesis.
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.
Human mammary cancer as a site of sex steroid metabolism.
Identification of albumin in breast tumor cytosol as a factor involved in the stimulation of estradiol 17 beta-hydroxysteroid dehydrogenase (reductive) activity.
Importance of estrogen sulfates in breast cancer.
In situ production of estrogens in human breast carcinoma.
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells.
Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antiestrogens.
Interactive effects of interleukin-6, 17 beta-estradiol and progesterone on growth and 17 beta-hydroxysteroid dehydrogenase activity in human breast carcinoma cells.
Interleukin-3: a putative protective factor against breast cancer which is secreted by male but not female breast fibroblasts.
Intracrine mechanism of estrogen synthesis in breast cancer.
Kinetic studies of oestradiol 17 beta-hydroxysteroid dehydrogenase in MCF-7 mammary cancer cells.
New development in intracrinology of breast carcinoma.
Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. Effect on sulfatase activity in comparison to medroxyprogesterone acetate.
Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer.
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Regulation of 17 beta-hydroxysteroid dehydrogenase in a newly-established human breast carcinoma cell line.
Regulation of estradiol 17 beta-hydroxysteroid dehydrogenase expression and activity by retinoic acid in T47D breast cancer cells.
Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells.
Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer.
Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer.
Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Role, control and expression of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase activities in human breast cancer.
Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
Synergistic interaction of growth factors and albumin in regulating estradiol synthesis in breast cancer cells.
The effect of breast tumour and normal breast tissue cytosols on oestradiol 17 beta-hydroxysteroid dehydrogenase activity.
The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue.
The role and proposed mechanism by which oestradiol 17 beta-hydroxysteroid dehydrogenase regulates breast tumour oestrogen concentrations.
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
The SEEM: selective estrogen enzyme modulators in breast cancer.
The selective estrogen enzyme modulator (SEEM) in breast cancer.
The selective estrogen enzyme modulators in breast cancer: a review.
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
[Evaluation of 17-beta-hydroxysteroid dehydrogenase activity as a marker of the hormone dependence of breast cancers]
Carcinoma
16 alpha-iodo-3,17 beta-estradiol: a stable ligand for estrogen receptor determinations in tissues with high 17 beta-hydroxysteroid dehydrogenase activity.
17 beta-hydroxysteroid dehydrogenase deficiency in malignant interstitial cell carcinoma of the testis.
Adrenocortical cytopathology.
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Characterization of rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues.
Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in the rat: a model of postmenopausal breast cancer.
Estradiol and progestin receptors, 17-beta-hydroxysteroid-dehydrogenase and histopathologic grade in endometrial carcinoma.
Expression of human 17 beta-hydroxysteroid dehydrogenase in mammalian cells.
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Partial purification and evidence for heterogeneity of the cytoplasmic 17beta-hydroxysteroid dehydrogenase (17beta-HSD) from normal human endometrium and endometrical carcinoma.
Steroid biosynthesis in human adrenal tumors.
Steroid-converting enzymes in human ovarian carcinomas.
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Carcinoma, Ductal
17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters.
Carcinoma, Embryonal
Evidence of 3 beta-hydroxysteroid dehydrogenase activity in several murine embryonal carcinoma cell lines.
Carcinoma, Endometrioid
The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma.
Carcinoma, Hepatocellular
Deletion mapping of chromosome 16q24 in hepatocellular carcinoma in Taiwan and mutational analysis of the 17-beta-HSD gene localized to the region.
Carcinoma, Intraductal, Noninfiltrating
17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Cholera
Hormonal regulation of androgen biosynthesis by primary cultures of testis cells from neonatal rats.
cholesterol monooxygenase (side-chain-cleaving) deficiency
17 alpha-hydroxylation deficiency.
Choriocarcinoma
17 beta-Hydroxysteroid dehydrogenase: enzymatic activity and mRNA species in choriocarcinoma cells.
Characterization of 17 beta-hydroxysteroid dehydrogenase type 1 in choriocarcinoma cells: regulation by basic fibroblast growth factor.
Phosphorylation of 17 beta-hydroxysteroid dehydrogenase in BeWo choriocarcinoma cells.
Regulation of 17 beta-hydroxysteroid dehydrogenase type 1 by epidermal growth factor and transforming growth factor-alpha in choriocarcinoma cells.
Regulation of 3 beta-hydroxysteroid dehydrogenase and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels by cyclic adenosine 3',5'-monophosphate and phorbol myristate acetate in human choriocarcinoma cells.
Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells.
Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
[Regulation of human 17 beta-hydroxysteroid dehydrogenase type 1 expression by cyclic adenosine 3',5'-monophosphate in choriocarcinoma cells]
Colonic Neoplasms
17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.
Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer.
Oestrogen inactivation in the colon: analysis of the expression and regulation of 17beta-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer.
Cryptorchidism
Influence of experimental cryptorchidism on cholesterol side-chain cleavage enzyme and delta5-3beta-hydroxysteroid dehydrogenase activities in rat testes.
Phospholipid hydroperoxide glutathione peroxidase is involved in the maintenance of male fertility under cryptorchidism in mice.
Cushing Syndrome
Enzyme histo-cytochemical studies in human adrenocortical adenomas. [II] Cushing's syndrome.
Experience with trilostane in the treatment of Cushing's syndrome.
Investigation of urinary steroid profiles as a diagnostic method in Cushing's syndrome.
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas.
Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
Trilostane and the normal hypothalamic-pituitary-testicular axis.
[Effect of a 3 beta-hydroxysteroid dehydrogenase inhibitor (trilostane) on Cushing's syndrome]
Cystic Fibrosis
Regulation of Wolffian duct development.
Cysts
Changes in the forward and reverse metabolism of aromatizable androgens during the development of large ovarian cysts in the pregnant rat.
Dominant bovine ovarian follicular cysts express increased levels of messenger RNAs for luteinizing hormone receptor and 3 beta-hydroxysteroid dehydrogenase delta(4),delta(5) isomerase compared to normal dominant follicles.
Molecular characterisation of two novel 17beta-hydroxysteroid dehydrogenase genes from the soybean cyst nematode Heterodera glycines
Diabetes Mellitus, Type 1
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Diabetes Mellitus, Type 2
[Ginkgo biloba extract enhances testosterone synthesis of Leydig cells in type 2 diabetic rats]
Disorders of Sex Development
A (R80Q) mutation in 17 beta-hydroxysteroid dehydrogenase type 3 gene among Arabs of Israel is associated with pseudohermaphroditism in males and normal asymptomatic females.
Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase.
Characterization of two novel homozygous missense mutations involving codon 6 and 259 of type II 3beta-hydroxysteroid dehydrogenase (3betaHSD) gene causing, respectively, nonsalt-wasting and salt-wasting 3betaHSD deficiency disorder.
Complexities of gender assignment in 17beta-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for early orchiectomy?
Mutation in 3 beta-hydroxysteroid dehydrogenase type II associated with pseudohermaphroditism in males and premature pubarche or cryptic expression in females.
Progressive virilization of a pubertal phenotypic female: 17 beta-hydroxysteroid dehydrogenase deficiency.
Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women.
Use of laparoscopy in intersex patients.
[Case report: congenital adrenal hyperplasia and ambiguous genitalia due to 3 beta-hydroxysteroid dehydrogenase deficiency]
Endometrial Hyperplasia
In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia.
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.
Endometrial Neoplasms
17 beta-Hydroxysteroid dehydrogenase activity in endometrial cancer cells: different metabolic pathways of estradiol in hormone-responsive and non-responsive intact cells.
Leydig cell tumor of the ovary associated with endometrial carcinoma and containing 17 beta-hydroxysteroid dehydrogenase.
Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
On the mitochondrial 17beta-hydroxysteroid dehydrogenase from human endometrium and endometrial carcinoma: characterization and intramitochondrial distribution.
Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer.
Short-term effects of danazol and medroxyprogesterone acetate on cytosol and nuclear estrogen and progestin receptors, 17 beta-hydroxysteroid dehydrogenase activity, histopathology, and ultrastructure of human endometrial adenocarcinoma.
Studies on 17 beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma. III. Partial purification and characterization of the microsomal enzyme.
Studies on 17beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma I. Subcellular distribution and variations of specific enzyme activity.
Studies on 17beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma.
The role of tissue steroids in regulating aromatase and oestradiol 17 beta-hydroxysteroid dehydrogenase activities in breast and endometrial cancer.
[Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)]
Endometriosis
Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection.
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
Effect of gestrinone in endometriosis tissue and endometrium.
Endometriosis expresses a molecular pattern consistent with decreased retinoid uptake, metabolism and action.
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis.
Expression of 17beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis.
Mechanisms of excessive estrogen formation in endometriosis.
Role of aromatase in endometrial disease.
Steroidal regulation of endometriosis tissue: lack of induction of 17 beta-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol.
Fibroadenoma
Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas.
Fibroma
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
Follicular Cyst
Dominant bovine ovarian follicular cysts express increased levels of messenger RNAs for luteinizing hormone receptor and 3 beta-hydroxysteroid dehydrogenase delta(4),delta(5) isomerase compared to normal dominant follicles.
Late-onset 3 beta-hydroxysteroid dehydrogenase deficiency with virilization induced by a large ovarian cyst.
Fowlpox
Deletion of fowlpox virus homologues of vaccinia virus genes between the 3 beta-hydroxysteroid dehydrogenase (A44L) and DNA ligase (A50R) genes.
Glioma
Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
The influence of haemoglobin-S and G6PD deficiency on the activity of the 17 beta-hydroxysteroid dehydrogenase of intact human erythrocytes.
Glucosephosphate Dehydrogenase Deficiency
The influence of haemoglobin-S and G6PD deficiency on the activity of the 17 beta-hydroxysteroid dehydrogenase of intact human erythrocytes.
Gonadal Dysgenesis
46,XX pure gonadal dysgenesis with growth hormone deficiency and impaired 3 beta-hydroxysteroid dehydrogenase activity.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Gonadal Dysgenesis, Mixed
Masculinizing genitoplasty in intersex patients.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Use of laparoscopy in intersex patients.
Gynecomastia
Male pseudohermaphroditism due to nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency: gender role change and absence of gynecomastia at puberty.
Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male.
Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17.
Heart Failure
A case of neonatal McCune-Albright syndrome with Cushing syndrome and hyperthyroidism.
Heart Septal Defects, Atrial
Male pseudohermaphroditism due to 3 beta-hydroxysteroid dehydrogenase-isomerase deficiency associated with atrial septal defect.
Herpes Zoster
Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies.
Histochemical observations on the adrenal gland of bat Vesperugo pipistrellus (Dobson).
Serum steroids and success of corticotropin therapy in infantile spasms.
Spatiotemporal changes in cytokeratin expression in the neonatal rat ovary.
Studies of adrenal steroidogenic enzymes in guinea pigs.
The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3 beta-hydroxysteroid dehydrogenase.
Hirsutism
Congenital adrenal hyperplasia.
Hirsutism due to late onset 3 beta-hydroxysteroid dehydrogenase deficiency.
Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women.
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency in children with accelerated growth, premature pubarche and/or hirsutism.
No genetic mutation in type II 3 beta-hydroxysteroid dehydrogenase gene in patients with biochemical evidence of enzyme deficiency.
Nonclassical 3 beta-hydroxysteroid dehydrogenase deficiency in young girls with hirsutism and premature pubarche.
Normal ovarian function in a mild form of late-onset 3 beta-hydroxysteroid dehydrogenase deficiency.
Partial 3 beta-hydroxysteroid dehydrogenase deficiency presenting as new-onset gynecomastia in a eugonadal adult male.
Serum and urinary steroids in girls with precocious pubarche and/or hirsutism due to mild 3-beta-hydroxysteroid dehydrogenase deficiency.
The human 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene cluster on chromosome 1p13 contains a presumptive pseudogene; 3 beta-HSD and CYP17 do not segregate with dominantly inherited hirsutism.
The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia.
[3 beta-hydroxysteroid dehydrogenase deficiency and 21-hydroxylase deficiency in hirsutism]
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
Hydatidiform Mole
Kinetic analysis of 3 beta-hydroxysteroid dehydrogenase activity in microsomes from complete hydatidiform mole.
Plasma hormone concentrations and serum 17 beta-hydroxysteroid dehydrogenase activity in molar pregnancy.
Hyperaldosteronism
Inhibition of furosemide-induced kaliuresis in the rat by trilostane, an inhibitor of adrenal steroidogenesis.
Long-term treatment of idiopathic hyperaldosteronism using trilostane.
Mild adrenal 3 beta-hydroxysteroid dehydrogenase deficiency with hyperaldosteronism.
Primary aldosteronism: treatment with trilostane.
The inhibiting effect of trilostane on testosterone synthesis. Hormonal and morphologic alterations induced by subchronic trilostane treatment in rats and healthy volunteers.
Hyperandrogenism
3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism.
Hyperandrogenism due to 3 beta-hydroxysteroid dehydrogenase deficiency with accessory adrenocortical tissue: a hormonal and metabolic evaluation.
Hyperandrogenism: new insights into etiology, diagnosis, and therapy.
Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome.
The incidence of late-onset congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency among hirsute women.
[Late onset hyperandrogenism caused by 3-beta-hydroxysteroid dehydrogenase deficiency]
Hyperprolactinemia
Metoclopramide-induced hyperprolactinaemia: effects on corpus luteum function, endometrial steroid receptor concentrations and 17 beta-hydroxysteroid dehydrogenase activity.
Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia.
Prolactin has a direct effect on adrenal androgen secretion.
Regulation of 3 beta-hydroxysteroid dehydrogenase activity in rat testis under hyperprolactinemia and excessive 17 beta-estradiol.
The effects of prolactin on rat ovarian function.
The effects of prolactin on rat testicular steroidogenic enzyme activities.
Hypertension
Steroid characteristics of mineralocorticoid adrenocortical hypertension.
The inhibiting effect of trilostane on testosterone synthesis. Hormonal and morphologic alterations induced by subchronic trilostane treatment in rats and healthy volunteers.
Hypogonadism
[Clinical features and diagnosis of mild 3-beta-hydroxysteroid dehydrogenase deficiency in men]
[Disorder of 17 beta-hydroxysteroid dehydrogenase as the cause of hypergonadotropic hypogonadism in 2 siblings with primary amenorrhea]
Hypospadias
Molecular study of the 3 beta-hydroxysteroid dehydrogenase gene type II in patients with hypospadias.
The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias.
Infertility
Congenital adrenal hyperplasia.
[17 beta hydroxysteroid dehydrogenase and creatine phosphokinase activities and the levels of sex hormones and their receptors in the uterus of patients with fibromyoma or endocrine sterility]
[Clinical features and diagnosis of mild 3-beta-hydroxysteroid dehydrogenase deficiency in men]
Insulin Resistance
Steroidogenic alterations and adrenal androgen excess in PCOS.
Klinefelter Syndrome
Masculinizing genitoplasty in intersex patients.
Leiomyoma
17 beta-hydroxysteroid dehydrogenase activity in leiomyoma and myometrium and its relationship to concentrations of oestrone, oestradiol and progesterone throughout the menstrual cycle.
Aromatase and leiomyoma of the uterus.
Endometriosis: the pathophysiology as an estrogen-dependent disease.
In vitro conversion of estradiol-17beta into estrone in normal human myometrium and leiomyoma.
Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma.
[17 beta hydroxysteroid dehydrogenase and creatine phosphokinase activities and the levels of sex hormones and their receptors in the uterus of patients with fibromyoma or endocrine sterility]
Leukemia
Differential gene regulation by estrogen and progesterone in the primate endometrium.
Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells.
Leydig Cell Tumor
Histogenesis, cytodifferentiation, and its subcellular steroidogenic sites in the virilizing ovarian Leydig cell tumor: light microscopic dry-mounting radioautography for [3H]cholesterol and electron microscopic cytochemistry for 3 beta-hydroxysteroid dehydrogenase activity.
Leydig cell tumor of the ovary associated with endometrial carcinoma and containing 17 beta-hydroxysteroid dehydrogenase.
Melanoma
Sebocytes are the key regulators of androgen homeostasis in human skin.
Meningioma
17 beta-Hydroxysteroid dehydrogenase activity correlates with the type-2 17 beta-hydroxysteroid dehydrogenase mRNA abundance in human meningioma tumors.
Biochemical characterization of 17 beta-hydroxysteroid dehydrogenase in human meningioma.
Characterization of 17 beta-hydroxysteroid dehydrogenase activity and mRNA abundance in human meningioma tumors.
Mineralocorticoid Excess Syndrome, Apparent
Steroid characteristics of mineralocorticoid adrenocortical hypertension.
Neoplasm Metastasis
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Neoplasms
17 beta-Hydroxysteroid dehydrogenase activity correlates with the type-2 17 beta-hydroxysteroid dehydrogenase mRNA abundance in human meningioma tumors.
17 beta-hydroxysteroid dehydrogenase in common epithelial ovarian tumors.
A virilizing adrenal tumor with borderline elevation of urinary 17-ketosteroids and histochemical demonstration of a deficiency in the delta 5/delta 4-isomerase, 3 beta-hydroxysteroid dehydrogenase enzymatic system.
A virilizing adrenocortical tumor in a female infant: in vivo and in vitro biochemical characteristics.
Acid phosphatases of dog testis and a Leydig cell tumor.
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Aromatase inhibitor development for treatment of breast cancer.
Characterization of 17 beta-hydroxysteroid dehydrogenase activity and mRNA abundance in human meningioma tumors.
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary.
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in normal and carcinomatous endometrium.
Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21.
Determinants of tissue oestradiol levels in human breast cancer.
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase Type 3.
Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in the rat: a model of postmenopausal breast cancer.
Effects of LH and oestrogen on the growth of feminising testicular tumours in mice.
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Establishment and further characterization of a line of transgenic mice showing testicular tumorigenesis at 100% incidence.
Estradiol and progestin receptors, 17-beta-hydroxysteroid-dehydrogenase and histopathologic grade in endometrial carcinoma.
Estrogen inhibits cell proliferation through in situ production in human thymoma.
Expression of COX-2 and steroid converting enzymes in breast cancer.
Expression of human 17 beta-hydroxysteroid dehydrogenase in mammalian cells.
Histogenesis, cytodifferentiation, and its subcellular steroidogenic sites in the virilizing ovarian Leydig cell tumor: light microscopic dry-mounting radioautography for [3H]cholesterol and electron microscopic cytochemistry for 3 beta-hydroxysteroid dehydrogenase activity.
HPLC-RIA analysis of steroid hormone profile in a virilizing stromal tumor of the ovary.
Immunohistochemical and biochemical analysis of a human Sertoli-Leydig cell tumor: autonomous steroid production characteristic of ovarian theca cells.
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
In vitro pregnenolone metabolism by mouse adrenal gland: II-Biosynthesis of androgens.
Increased 17 beta-hydroxysteroid dehydrogenase activity in a masculinizing adrenal adenoma in a patient with isolated testosterone overproduction.
Inhibin and activin differentially regulate androgen production and 17 alpha-hydroxylase expression in human ovarian thecal-like tumor cells.
Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Isolated dehydroepiandrosterone sulphate hypersecretion: a case report.
Leydig cell tumor of the ovary associated with endometrial carcinoma and containing 17 beta-hydroxysteroid dehydrogenase.
Loss of estrogen inactivation in colonic cancer.
Measurement of steroidogenesis in rodent Leydig cells: a comparison between pregnenolone and testosterone production.
Metabolism of estradiol by human breast cancer.
Oxidations of 17beta-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or beta-naphthoflavone.
Presence of 17 beta-hydroxysteroid dehydrogenase type 3 messenger ribonucleic acid transcript in an ovarian Sertoli-Leydig cell tumor.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue.
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer.
Small adrenocortical tumors without apparent clinical endocrine abnormalities. Immunolocalization of steroidogenic enzymes.
Steroid biosynthesis in human adrenal tumors.
Steroid cell tumor associated with primary amenorrhea and virilization.
Steroid metabolism by a tumour of the specific gonadal stroma in a child.
Steroid metabolism by normal and neoplastic parotid tissue.
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution.
The effect of ethynyloestradiol and medroxyprogesterone acetate on the in vivo uptake and metabolism of 3H-oestradiol by breast tumour tissue in postmenopausal women.
The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model.
The effects of hydrogen peroxide on steroidogenesis in mouse Leydig tumor cells.
The mouse inhibin alpha-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice.
The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium.
The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer.
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Type beta 1 transforming growth factor is an inhibitor of 3 beta-hydroxysteroid dehydrogenase isomerase in mouse adrenal tumor cell line Y1.
Young female patient with testosterone-producing adrenocortical adenoma also showing signs of subclinical Cushing's syndrome.
[Diseases caused by adrenal dyshormonogenesis. The concept of minor enzymopathy. The 3 beta-hydroxysteroid dehydrogenase block; its possible importance in the pathogenesis of breast cancer]
[Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)]
[Expression of human 17 beta-hydroxysteroid dehydrogenase gene in BmNPV expression system]
[Metabolism of androgens in various histological variants of bone tumors]
Obesity
Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5.
Osteoarthritis
Estrogen metabolism, not biosynthesis, in rabbit articular cartilage and isolated chondrocytes: a preliminary study.
Ovarian Cysts
Changes in the forward and reverse metabolism of aromatizable androgens during the development of large ovarian cysts in the pregnant rat.
Late-onset 3 beta-hydroxysteroid dehydrogenase deficiency with virilization induced by a large ovarian cyst.
Ovarian Diseases
Experimental micropolycystic ovarian disease. I. Measurement of body weight, ovarian weight and histochemical activity of 17 beta-hydroxysteroid dehydrogenase.
Polycystic ovarian disease and congenital and late-onset adrenal hyperplasia.
The response of several adrenocortical steroids to the administration of ACTH in hirsute women.
Ovarian Neoplasms
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Peripheral Nerve Injuries
Increased expression of 3 beta-hydroxysteroid dehydrogenase mRNA in dorsal root ganglion neurons of adult rats following peripheral nerve injury.
Peroxisomal Disorders
Molecular changes in the D-bifunctional protein cDNA sequence in Australasian patients belonging to the bifunctional protein complementation group.
Polycystic Ovary Syndrome
5 alpha-reductase activity in polycystic ovary syndrome.
Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Polycystic ovary syndrome: evidence for reduced 3 beta-hydroxysteroid dehydrogenase gene expression in human luteinizing granulosa cells.
The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.
[Partial 3-beta-hydroxysteroid dehydrogenase deficiencies]
Polycythemia
Serum testosterone levels and excessive erythrocytosis during the process of adaptation to high altitudes.
Polyendocrinopathies, Autoimmune
3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure.
Prolactinoma
Altered profile of endogenous steroids in the urine of patients with prolactinoma.
Prostatic Hyperplasia
17 beta-Hydroxysteroid dehydrogenase in the human prostate: properties and distribution between epithelium and stroma in benign hyperplastic tissue.
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Expression of enzymes involved in estrogen metabolism in human prostate.
Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids.
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Prostatic Intraepithelial Neoplasia
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Prostatic Neoplasms
17beta-hydroxysteroid dehydrogenase type 11 (Pan1b) expression in human prostate cancer.
3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase Type 3.
Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues.
Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells.
Genetic susceptibility to cancer from exogenous and endogenous exposures.
Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk.
In situ androgen producing enzymes in human prostate cancer.
Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells.
Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue.
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human prostate cancer cells.
Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.
The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Sertoli-Leydig Cell Tumor
Presence of 17 beta-hydroxysteroid dehydrogenase type 3 messenger ribonucleic acid transcript in an ovarian Sertoli-Leydig cell tumor.
Sex Cord-Gonadal Stromal Tumors
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
Smallpox
Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus.
Starvation
Effects of starvation in rats on serum levels of testosterone, dihydrotestosterone and testicular 3 beta-hydroxysteroid dehydrogenase activity.
steroid 11beta-monooxygenase deficiency
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
Congenital adrenal hyperplasia in pregnancy.
Congenital adrenal hyperplasia in Turkey: a review of 273 patients.
Congenital adrenal hyperplasia.
Defects in steroidogenic enzymes. Discrepancies between clinical steroid research and molecular biology results.
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
Molecular basis of congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency.
steroid 21-monooxygenase deficiency
3 alpha-Androstanediol glucuronide in premature and normal pubarche.
Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche.
Congenital adrenal hyperplasia in pregnancy.
Congenital adrenal hyperplasia.
Diagnosis of homozygosity and heterozygosity in congenital adrenal hyperplasia (CAH) and control of treatment.
Late-onset adrenal steroid 3 beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women.
[3 beta-hydroxysteroid dehydrogenase deficiency and 21-hydroxylase deficiency in hirsutism]
Stiff-Person Syndrome
Stiff-man syndrome: identification of 17 beta-hydroxysteroid dehydrogenase type 4 as a novel 80-kDa antineuronal antigen.
Thecoma
Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary.
Tics
Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells.
Vaccinia
Deletion of fowlpox virus homologues of vaccinia virus genes between the 3 beta-hydroxysteroid dehydrogenase (A44L) and DNA ligase (A50R) genes.
Expansion of the mammalian 3 beta-hydroxysteroid dehydrogenase/plant dihydroflavonol reductase superfamily to include a bacterial cholesterol dehydrogenase, a bacterial UDP-galactose-4-epimerase, and open reading frames in vaccinia virus and fish lymphocystis disease virus.
Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus.
Varicose Veins
Elevated sex steroid hormones in great saphenous veins in men.
Wilms Tumor
Starvation is more efficient than the washing technique for purification of rat Sertoli cells.